Ion channel

Three Exiger Executives Awarded 2024 Pros to Know by Supply & Demand Chain Executive

Retrieved on: 
Monday, March 11, 2024
UX, Risk management, Growth, Non-governmental organization, Carbon accounting, Acquisition, Software, Top, Ion channel, SCRM, Food, Demand

NEW YORK, March 11, 2024 /PRNewswire/ -- Exiger, the market-leading supply chain and third-party risk AI company, announced today that three members of its executive team have been recognized with the 2024 Pros to Know award by Supply & Demand Chain Executive – the only publication covering the entire supply chain.

Key Points: 
  • NEW YORK, March 11, 2024 /PRNewswire/ -- Exiger, the market-leading supply chain and third-party risk AI company, announced today that three members of its executive team have been recognized with the 2024 Pros to Know award by Supply & Demand Chain Executive – the only publication covering the entire supply chain.
  • "Many of today's supply chain pros are more than just leaders within their space; they're innovators, decision makers, pioneers of change and growth.
  • They've spent the last year (and more) creating safer, more efficient supply chains," said Marina Mayer, Editor-in-Chief of Food Logistics and Supply & Demand Chain Executive.
  • This year's award winners are profiled in Supply & Demand Chain Executive's March 2024 issue, which will be distributed at MODEX 2024 and at www.SDCExec.com .

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024
BIA, BGF, Biotechnology, Ion channel, COVID-19, Cytomegalovirus, Methamphetamine, UBS, Therapy, Asthma, Meetup, Disease, Venture, Innovation, ADHD, Safety, Frontotemporal dementia, Eurosport 1, AstraZeneca, Cocaine, CMV, Chair, COPD, Infection, Investment, LifeArc, AbCellera, Bose, Patient, Associate, G protein-coupled receptor, Partnership, Innovate UK, Merck Group, Ecosystem, PwC, FDA, System, Chronic pain, Clinical trial, News, Pharmaceutical industry

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.

LifeArc Ventures - six new investments, portfolio progress and an expanding investment team

Retrieved on: 
Thursday, January 25, 2024
BIA, BGF, Biotechnology, Ion channel, COVID-19, Cytomegalovirus, Methamphetamine, UBS, Therapy, Asthma, Meetup, Disease, Venture, Innovation, ADHD, Safety, Frontotemporal dementia, Eurosport 1, AstraZeneca, Cocaine, CMV, Chair, COPD, Infection, Investment, LifeArc, AbCellera, Bose, Patient, Associate, G protein-coupled receptor, Partnership, Innovate UK, Merck Group, Ecosystem, PwC, FDA, System, Chronic pain, Clinical trial, News, Pharmaceutical industry

LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.

Key Points: 
  • LifeArc Ventures' portfolio grew in 2023, as we invested in five companies and co-founded one new company across the therapeutics and healthtech space.
  • We have expanded our investment team, adding two new members and further strengthened our Early Ventures Investment Committee through the appointment of a new Chair and new independent member.
  • Jon joined us from M Ventures' biotechnology investment team and previously was an associate within the healthcare investment banking team at UBS, after starting his career as a doctor.
  • In addition, Clare Terlouw, Head of LifeArc Ventures, was re-elected to the BioIndustry Association (BIA) Board of Directors for the third time.

Department of the Interior Awards Exiger and InterSec Five-Year $7 Million C-SCRM Contract

Retrieved on: 
Thursday, January 11, 2024
SCRM, Ion channel, Partnership, Software as a service, Intelligence, Risk, Software, Interior, Cabinet, ICT, FedRAMP, SBOM, Unitary state, DOI, Small business, Machine learning, Government, Federation, Medical device

WASHINGTON, Jan. 11, 2024 /PRNewswire/ -- Exiger, the SaaS company revolutionizing the way corporations, government agencies and banks manage supply chains, and InterSec, a small business and one-stop cybersecurity service provider, announced today that they were awarded a competitive $7 million contract from the Department of the Interior (DOI) to provide enterprise cyber supply chain risk management (C-SCRM) labor and software. The contract with the Cabinet-level agency will scale over a five-year period.

Key Points: 
  • The contract with the Cabinet-level agency will scale over a five-year period.
  • "We look forward to collaborating with InterSec and leveraging their deep C-SCRM subject matter expertise to scale this partnership model for future federal opportunities."
  • "The cyber supply chain security landscape is extremely complex and lacks the systematic rigor required to assess the risk and proactively secure the supply chain.
  • InterSec, serving as the prime, will provide program management support drawing on its deep cybersecurity domain expertise and experience in building and implementing a C-SCRM as a service for the Department of the Interior.

Autifony Announces Exclusive Global License and Collaboration Agreement with Jazz Pharmaceuticals on Two Ion Channel Targets for Neurological Disorders

Retrieved on: 
Tuesday, November 14, 2023
Biotechnology, Neurology, Health, Pharmaceutical, Clinical Trials, CNS, Ion channel, Noetics, Membrane, Therapy, Gene, Myenteric plexus, DSM-IV codes, Jazz Pharmaceuticals, Eurosport 1, Patient, Medicine, Movement, Central nervous system disease, Drug discovery, Pharmaceutical industry, Vaccine, Jazz

Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, today announced that it has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) for up to $770.5 million to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders.

Key Points: 
  • Autifony Therapeutics Limited (“Autifony”), which is pioneering the development of novel pharmaceutical treatments for rare CNS disorders and other serious brain diseases, today announced that it has entered into an exclusive global licensing agreement with Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (Jazz) for up to $770.5 million to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders.
  • Autifony will lead drug discovery and preclinical development activities on the two targets.
  • Subsequent to successful completion of such preclinical development, Jazz will lead all clinical development, manufacturing and regulatory activities and commercialization.
  • Under the terms of the agreement, Autifony will receive an upfront payment from Jazz and is eligible to receive development, regulatory and commercial milestone payments across the two programmes.

Exiger Named One of Fast Company's 'Brands That Matter'

Retrieved on: 
Tuesday, October 3, 2023
Autumn, Software as a service, Lotus Exige, B2B, Association of British HealthTech Industries, Ion channel, Acquisition, UX, Government, AI, M&M, Environment, Dungeons & Dragons

WASHINGTON, Oct. 3, 2023 /PRNewswire/ -- Fast Company unveiled today its third annual Brands That Matter list, honoring brands that communicate and demonstrate brand purpose. Exiger, the SaaS company revolutionizing the way corporations, government agencies and banks manage supply chains, is pleased to be recognized amongst this year's Brands That Matter. The brands honored by Fast Company have built cultural relevance and impact through compelling branding and efforts that naturally extend their presence into the community.

Key Points: 
  • The brands honored by Fast Company have built cultural relevance and impact through compelling branding and efforts that naturally extend their presence into the community.
  • "Exiger is thrilled to be named alongside world-leading brands making a difference in their industries and in society," said Exiger CEO Brandon Daniels , who was recently accepted into Fast Company's Impact Council, an invitation-only collective of innovative leaders.
  • Exiger is at the forefront of empowering business leaders with AI to regain control of their supplier ecosystems.
  • The full list is available online here and will also be featured in the Fall issue of Fast Company magazine.

Exiger Named One of Fast Company's 'Brands That Matter'

Retrieved on: 
Tuesday, October 3, 2023
Autumn, Software as a service, Lotus Exige, B2B, Association of British HealthTech Industries, Ion channel, Acquisition, UX, Government, AI, M&M, Environment, Dungeons & Dragons

WASHINGTON, Oct. 3, 2023 /PRNewswire/ -- Fast Company unveiled today its third annual Brands That Matter list, honoring brands that communicate and demonstrate brand purpose. Exiger, the SaaS company revolutionizing the way corporations, government agencies and banks manage supply chains, is pleased to be recognized amongst this year's Brands That Matter. The brands honored by Fast Company have built cultural relevance and impact through compelling branding and efforts that naturally extend their presence into the community.

Key Points: 
  • The brands honored by Fast Company have built cultural relevance and impact through compelling branding and efforts that naturally extend their presence into the community.
  • "Exiger is thrilled to be named alongside world-leading brands making a difference in their industries and in society," said Exiger CEO Brandon Daniels , who was recently accepted into Fast Company's Impact Council, an invitation-only collective of innovative leaders.
  • Exiger is at the forefront of empowering business leaders with AI to regain control of their supplier ecosystems.
  • The full list is available online here and will also be featured in the Fall issue of Fast Company magazine.

Exiger Unveils 1Exiger, A Comprehensive New UX Designed to Make Supply Chain Management Simple, Intuitive and Accessible

Retrieved on: 
Tuesday, September 19, 2023
Ion channel, Policy, UX, Public sector, Government, Software as a service, SDX, AI, Acquisition, Lotus Exige, Glass, Ciso Morales, Risk, Retail

WASHINGTON, Sept. 19, 2023 /PRNewswire/ -- Exiger, the SaaS company revolutionizing the way corporations, government agencies and banks manage supply chains, today announced the launch of 1Exiger, a comprehensive, new supply chain platform and UX. 1Exiger houses Exiger's integrated suite of award-winning artificial intelligence solutions within a single platform, and makes available to the market the first end-to-end supply chain resilience environment that's designed to empower confident, auditable and rapid decisions informed by real-time insights.

Key Points: 
  • WASHINGTON, Sept. 19, 2023 /PRNewswire/ -- Exiger , the SaaS company revolutionizing the way corporations, government agencies and banks manage supply chains, today announced the launch of 1Exiger, a comprehensive, new supply chain platform and UX.
  • "Supply chain officers, procurement officers, CISOs, compliance leaders and counterintelligence officers are drowning in a deluge of risk alerts and data," said Exiger CEO Brandon Daniels .
  • "We've invested over the last two years to develop a seamless, intuitive solution to this problem.
  • In May, the company completed its acquisition of Ion Channel , a best-in-class software supply chain risk management platform, following last year's acquisition of Supply Dynamics .

Exiger Unveils 1Exiger, A Comprehensive New UX Designed to Make Supply Chain Management Simple, Intuitive and Accessible

Retrieved on: 
Tuesday, September 19, 2023
Ion channel, Policy, UX, Public sector, Government, Software as a service, SDX, AI, Acquisition, Lotus Exige, Glass, Ciso Morales, Risk, Retail

WASHINGTON, Sept. 19, 2023 /PRNewswire/ -- Exiger, the SaaS company revolutionizing the way corporations, government agencies and banks manage supply chains, today announced the launch of 1Exiger, a comprehensive, new supply chain platform and UX. 1Exiger houses Exiger's integrated suite of award-winning artificial intelligence solutions within a single platform, and makes available to the market the first end-to-end supply chain resilience environment that's designed to empower confident, auditable and rapid decisions informed by real-time insights.

Key Points: 
  • WASHINGTON, Sept. 19, 2023 /PRNewswire/ -- Exiger , the SaaS company revolutionizing the way corporations, government agencies and banks manage supply chains, today announced the launch of 1Exiger, a comprehensive, new supply chain platform and UX.
  • "Supply chain officers, procurement officers, CISOs, compliance leaders and counterintelligence officers are drowning in a deluge of risk alerts and data," said Exiger CEO Brandon Daniels .
  • "We've invested over the last two years to develop a seamless, intuitive solution to this problem.
  • In May, the company completed its acquisition of Ion Channel , a best-in-class software supply chain risk management platform, following last year's acquisition of Supply Dynamics .

Bionomics Announces Update on the α7 Nicotinic Acetylcholine Receptor (nAChR) Positive Allosteric Modulator (PAM) Collaboration with MSD

Retrieved on: 
Thursday, September 14, 2023
MSD, GABAA receptor positive allosteric modulator, Ion channel, Human, Society, Central nervous system, PAM, Royal Society of Chemistry, Pharmacokinetics, Research, RSC, Society of Chemical Industry, Patient, Chemical industry, DSM-IV codes, Acetylcholine, Merck, Merck & Co., SCI, PAMS, BioScience Research Collaborative, Pharmaceutical industry, Bionomics

MSD has subsequently developed MK-4334, a novel clinical candidate, which in early preclinical studies has shown improved drug like and pharmacological properties relative to BNC375.

Key Points: 
  • MSD has subsequently developed MK-4334, a novel clinical candidate, which in early preclinical studies has shown improved drug like and pharmacological properties relative to BNC375.
  • Under the 2014 exclusive Research Collaboration and License Agreement, MSD funds all research and clinical development, and worldwide commercialization of any resulting products.
  • This collaboration generated payments of $20M upfront and $10M for a Phase 1 milestone.
  • Bionomics is eligible to receive up to $465M in additional milestone payments for certain development and commercial milestones plus royalties on net sales of licensed drugs.